Fig. 4: Loss of CBX2 sensitizes HGSOC to chemotherapy.
From: CBX2 identified as driver of anoikis escape and dissemination in high grade serous ovarian cancer
a OVCAR4 shControl, shCBX2#1, and shCBX2#2 in 96-well plates treated over 24 h with increasing dose of cisplatin (0.5–100 µM). Percent cell viability was measured using the MTT assay and the half maximal inhibitory concentration (IC50) calculated. b Similarly to (a), OVCAR4 knockdown cell lines were grown in low adherent 96-well plates (forced suspension) and treated with increasing doses of cisplatin over 24 h and percent cell viability measured with MTT for calculation of IC50. c Annexin/V apoptosis assay of OVCAR4 cells grown in adherent setting with shControl, shCBX2#1 or #2 treated with cisplatin (10 µM) compared to untreated control. Percent Annexin positive cells are shown. Statistical test = ANOVA. Error bars = S.E.M.
